Nektar Therapeutics
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $55.2M | $98.4M | $90.1M | $92.1M | $101.9M | $152.9M | $114.6M | $1.19B |
| Cost of Revenue | $0 | $30.7M | $33.8M | $21.6M | $24.9M | $19.5M | $21.4M | $24.4M |
| Gross Profit | $55.2M | $67.7M | $56.4M | $70.4M | $77.0M | $133.4M | $93.2M | $1.17B |
| Gross Margin | 100.0% | 68.8% | 62.5% | 76.5% | 75.6% | 87.3% | 81.4% | 98.0% |
| Operating Expenses | ||||||||
| Research & Development | $117.3M | $120.9M | $114.2M | $218.3M | $400.3M | $408.7M | $434.6M | $399.5M |
| SG&A Expense | $68.7M | $76.8M | $77.4M | $92.3M | $122.8M | $104.7M | $98.7M | $81.4M |
| Operating Income | $-140.1M | $-105.2M | $-263.7M | $-376.2M | $-446.1M | $-425.1M | $-440.0M | $687.9M |
| Operating Margin | -253.7% | -106.9% | -292.6% | -408.6% | -437.8% | -278.0% | -383.9% | 57.6% |
| Interest Expense | — | — | — | $0 | $0 | $6.9M | $21.3M | $21.6M |
| Pretax Income | $-164.2M | $-119.2M | $-276.3M | $-365.0M | $-523.3M | $-443.9M | $-440.1M | $682.7M |
| Income Tax Expense | $-138.0K | $-239.0K | $-200.0K | $3.2M | $557.0K | $493.0K | $613.0K | $1.4M |
| Net Income | $-164.1M | $-119.0M | $-276.1M | $-368.2M | $-523.8M | $-444.4M | $-440.7M | $681.3M |
| Net Margin | -297.1% | -120.9% | -306.3% | -400.0% | -514.0% | -290.6% | -384.5% | 57.1% |
| EPS (Basic) | $-9.73 | $-8.68 | $-1.45 | $-1.97 | $-2.86 | $-2.49 | $-2.52 | $4.02 |
| EPS (Diluted) | $-9.73 | $-8.68 | $-1.45 | $-1.97 | $-2.86 | $-2.49 | $-2.52 | $3.78 |
| Shares Outstanding (Basic) | 16.9M | 13.7M | 190.0M | 187.1M | 183.3M | 178.6M | 175.0M | 169.6M |
| Shares Outstanding (Diluted) | 16.9M | 13.7M | 190.0M | 187.1M | 183.3M | 178.6M | 175.0M | 180.1M |
| Dividends Per Share | — | — | — | — | — | — | — | — |